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Introduction
Oral cancer is the fifth most common cancer in the
world, accounting for 412,000 new cases and 262,000
deaths annually in 1985, four-fifths of which occurred
in developing countries. Epidemiologic differences exist
in South Asia, where oral cancer ranks first among all
types of cancers in male patients and third in female
patients.1,2 Oral cancer is associated with chronic irri-
tating factors such as tobacco, smoking, alcohol, and
betel quid (BQ) use. While cigarette smoking and
alcohol drinking are the major risk factors in Western
countries, BQ use and smoking are major factors in the
causation of oral cancer in South Asia, Southeast Asia
and Taiwan.1–3 Oral cancer is a fatal disease, account-
ing for the fourth highest incidence of malignancy 
in males and the seventh in females in Taiwan. Oral
squamous cell carcinoma (OSCC) accounts for > 95%
of all oral malignancy. The relatively high prevalence
of oral cancer in Taiwan is mainly because there is a
high-risk group of 2.5 million people with the habits of
smoking and betel nut chewing. Oral mucosa diseases
such as leukoplakia, oral submucosa fibrosis, oral pre-
cancer lesions and oral cancer have been strongly asso-
ciated with the use of BQ.3,4 Unfortunately, around
50% of new cases at their first visit to our medical 
center often present with advanced TNM stage III or
IV lesions.4,5 It is generally accepted that prevention
and screening of oral cancer are equally important. In
this review article, we describe the nature of oral cancer
and highlight the various conventional and novel meth-
ods of screening for this disease and important related
research.
Importance of Early Treatment
Not only oral cancer, but also BQ-associated mouth
diseases such as mucositis, submucous fibrosis, severe
tooth attrition, and periodontitis have long been a
tough challenge in general health care. About 50% or
more of oral cancer patients have stage III or IV lesions
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at their first visit to our medical center in Taiwan.
Unfortunately, the overall 5-year survival rate of these
patients is poor despite recent advances in surgery, radio-
therapy and chemotherapy.5 Here, we give an example
to highlight the importance of early treatment.
A 50-year-old patient at his first visit to our depart-
ment presented with a growth measuring 4 × 5 cm 
in his right buccal mucosa-gingivae area and cervical
lymph adenopathy. OSCC T4N1M0 stage IV was
diagnosed after incision biopsy. The patient received a
commando operation with partial mandibulectomy
leaving a huge transbuccal defect. Radio-forearm fibu-
lar and anterior lateral tight free flaps were performed
for reconstruction. The patient received a 24-hour long
surgery, followed by a week of intensive medical care.
The final pathologic report confirmed the previous ten-
tative diagnosis. Afterwards, combination treatment
with concurrent chemotherapy and radiotherapy was
given. He suffered severe hair loss and radiotherapy-
burned facial skin. Unfortunately, the patient was diag-
nosed with distant lung metastasis 2 years after surgery.
Following consultation, chemotherapy and radiother-
apy were given as palliative treatment for 2 months to
control the metastatic neoplasm. Finally, the patient
died due to treatment failure. The expense of treatment
for this stage IV oral cancer patient was far more than
that for treating a stage I or II oral cancer patient.
Screening the High-risk Population
Oral cancer can be cured if treated early enough. Oral
cancer is one among the few human cancers with a
vast potential for prevention. Programs for detecting
oral cancer have been supported by our government
for many years. To cope with this program, funding
has been distributed in several directions, including 
to general health auxiliaries in public first-line health
care institutes, dentists and ENT doctors in medical
centers.3,4 However, the long-term effect remains to be
seen. Previous reports revealed that 90% of male oral
cancer patients were both BQ chewers and smokers.
It is undoubtedly the case that this high-risk group,
accounting for one-tenth of the population in Taiwan,
should be screened with priority. Meanwhile, a follow-
up system should be established to recall and monitor
the cancer patients and patients with precancerous
lesions who have been treated in hospital.5–8
Premalignant lesions predisposing to 
oral cancer
Attention should be paid specifically to precancerous
lesions.6–9 Leukoplakias are among the most common
potentially malignant oral lesions. Some are idiopathic,
while others are related to habits such as tobacco, alco-
hol or BQ use. About 80% of leukoplakias are benign,
with no evidence of dysplasia and no tendency to
malignancy, but biopsy is clearly indicated to define
the remaining 10–20% that are either dysplastic or
already changed to invasive carcinoma.6 Unfortunately,
there is currently no histologic or other means of reli-
ably predicting whether those leukoplakias will indeed
progress to malignancy. Overall, the rate of malignant
transformation of leukoplakias is about 3–6% over 
10 years, but rates that are much higher have been
reported. Medical management of leukoplakias includes
reducing or quitting those habits relating to risk factors,
increasing the intake of fruits and vegetables in the
diet, and possibly the use of active agents.7 Retinoids,
carotenoids and topical cytotoxic agents inducing
apoptosis show promise, and newer therapies are on
the horizon.7,9,10 Also, matrix metalloproteinase-13
(MMP-13) could be a potential tumor marker for
OSCC. Epigallocatechin-3-gallate, a component of
green tea, has also been demonstrated to inhibit oral
cancer through the modulation of MMP-13.11
Roles of Health Care Workers
Health care workers need to clearly understand their
roles in cancer screening. It is sometimes argued that
oral cancer screening is not necessary because routine
dental examinations should include a full oral mucosal
examination. However, apart from the fact that more
than 50% of the over-45-year-old population do not
attend a dentist annually, there is evidence that many
cases are missed, even by dental practitioners. This is
probably because early lesions are not specifically looked
for or may appear to be innocuous and are ignored.
Thus, other professions or specialists may also need to
be included in the screening program. Screening for
oral cancer is a simple, noninvasive procedure that can
be easily integrated into the comprehensive assessment
of older patients who account for the majority of oral
cancer patients. Further, geriatricians might feel more
comfortable performing an oral cancer screening
examination. Since 5-year survival rates are far greater
in individuals with localized lesions than in those with
distant metastases, the detection of early oral cancer
can make a significant positive contribution to prog-
nosis.12–14 Elderly persons at risk for oral cancer visit
their dentist far less frequently than they visit their
physician. Primary physicians look at sore throats every
day, and taking a few extra minutes to do a thorough
oral examination could benefit the patient. If primary
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care physicians joined in routinely screening for oral
cancer, long-term survival rates would undoubtedly
improve.
Methods of Screening
There are many reports on the miscellaneous methods
of oral cancer detection and screening.8,12–16 Physical
examination includes self-examination and clinical
examination. Clinicians have a responsibility to perform
a thorough head and neck examination as part of the
physical assessment of their patients. It takes less than
2 minutes to perform. The goal of examination is to
detect any nodules, swellings, mucosal alterations
(ulcerations, textural or color changes) and unexplained
neck lymph nodal adenopathy. While many routines
exist for an oral examination, each clinician must
develop his or her own method, use it in all patients,
and carefully document positive findings. Toluidine
blue staining is a simple method, with the dye having
an affinity to cancer cells. Commercial kits with proto-
col are available for large-scale screening of high-risk
populations or in clinical patients by topical application
or mouth rinsing. For subjects having panoral field
cancerization, rinsing or gargling is recommended.
However, a significant percentage of false-negatives and
false-positives exist.8,15,16
Meanwhile, a biopsy is still needed before a diagno-
sis can be confirmed. An excision biopsy is definitely
sufficient for pathologic analysis of small 0.5–1.0-cm
lesions. However, multiple incision biopsies are more
appropriate for a large lesion, which may also be stained
with toluidine blue to define highly suspected locations.
It is common to find cases with no definite lesion loca-
tion but rather a picture of panorally premalignant
cancerization in high-risk patients with a history of BQ
use and smoking for 20–30 years.5,8
Exfoliative cytology in screening for oral cancer has
never achieved the same success as it has for diagnosing
cancer of the uterine cervix. Oral exfoliative cytology
enjoyed much attention in the 1960s, but eventually
fell from favor, due largely to the subjective nature of
its interpretation, and also because the field canceriza-
tion led to it being extremely difficult to tell where
exactly cancer cells came from in early cancer cases.
The recent application of quantitative and immuno-
cytochemical techniques has, to some extent, refined
its potential role. However, the absence of a marker,
present in all malignant lesions but never in benign
lesions, limits its clinical utility.8,16 An additional 
drawback of exfoliative cytology for screening is that
the lesion still had to be identified or anatomically
located. Technical problems may also easily be
encountered in cases with field cancerization in betel
nut chewers.15–17
Saliva containing exfoliated cells from scraping or
natural exfoliation combined with Cytospin may be
another approach. Utilizing Cytospin preparation from
saliva may potentially increase the collected cellular
contents for analysis. Some squamous cell carcinoma
cytokeratin markers have been detected occasionally
at a higher level within serum in a few cancer patients.
However, unlike α-fetoprotein for hepatoma or some
important markers for prostate or other cancers, there
is no one specific marker that can be universally used for
the detection of oral cancer. Lacking profound hepatic
sinusoid circulation, the superficially located oral lesions
have not given a promising result so far.6,8,12 Current
molecular biology techniques may improve the cytology
screening method. The experimental data of Lin et al
showed initial success in detection of 3q26-27 onco-
gene amplification in laser-captured-microdissected
samples in the brushed buccal cells of betel chewers.18
David Wong from UCLA dental school has proposed
a new method for using pure saliva secreted from the
major or minor salivary glands without cellular con-
tent for cancer detection.19 This technique is powered
by nanotechnology, proteomics, and high throughput
microarray. Previously, the saliva has not been proven
to have any contribution for cancer detection. Two
salivary proteins, interleukin (IL)-8 and thioredoxin,
can be used to discriminate between the saliva of oral
cancer patients and that of control subjects. IL-8 is sig-
nificantly elevated in the saliva of oral cancer patients
and is highly discriminatory for detecting oral cancer in
saliva at a cut-off of 600 pg/mL. Similarly, oral cancer
patients have significantly higher salivary IL-8 mRNA
concentrations than control subjects. Both elevation
of IL-8 and IL-8 mRNA can discriminate inflamma-
tory disease such as periodontitis from oral cancer.19
It is accepted that oral exfoliative cytology can not
only assume a greater role by providing samples of
DNA for genetic analysis but can also provide a useful
tool for screening. The pendulum is swinging from
the morphologic picture towards the molecular level.
We may yet see a new role for exfoliative cytology.
Greater understanding of genetic aberrations may pre-
dict not only the biological behavior of the tumor but
also its likely response to both traditional and novel
forms of therapy. It remains to be seen if exfoliative
cytology can progress from being a research tool to
being used in routine clinical practice.12,13 The future
role for oral exfoliative cytology—bleak or bright? It
may well be that a more scientific and efficient method
for oral exfoliative cytology might enjoy greater success
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based on the understanding of the molecular mecha-
nism and characteristics of cancer development.
Mechanisms of Oral Cancer Formation
Similar to the well-established colorectal carcinoma
model, oral cancer is also considered to be a multi-hit
process involving a number of aberrant genetic events
culminating in malignant transformation at the molec-
ular and biological levels. It is known that following
the action of various carcinogens (chemical, physical,
biological) on normal cells in humans, a long period
(latency) of several months to years (∼10 months to
30 years) occurs between the development of precancer
cells and their transformation into cancer cells. How-
ever, the molecular and biological events that take place
within the precancer cells during this quiescent stage
are not yet fully understood. Recent studies revealed
that preneoplastic cell development and transforma-
tion into cancer cells is determined initially by genetic
changes (oncogenes, antioncogenes), with sequential
multiple somatic mutations, and later by epigenetic or
environmental cell factors such as hormones, growth
factors, cytokines, vitamins, and prostaglandins. These
factors can markedly change the evolution of preneo-
plastic cells by enhancing, retarding, or inhibiting their
transformation into cancer cells, or even reversing them
to a normal phenotype.1,2,9 These effects act on DNA,
RNA, and protein synthesis, as well as on cell replica-
tion, cell cycles, cell surfaces, and intercellular commu-
nication. Therefore, these abnormal DNA, oncogenes
or tumor suppressor genes, and ultrastructural intra-
cellular or cell surface antigenic determinants as poten-
tial biomarkers are essential for early detection of
preneoplastic cells and cancer cells. A significant recent
advance is the gradual understanding of the molecular
mechanism of oral cancer formation.20–33 Although a
universal tumor marker is still lacking for oral cancer,
a combination of several markers may be useful and
more accurate.
BQ-associated Chemical Carcinogenesis
BQ users as a group are seen as being at highest risk of
oral cancer in Taiwan. This is because the areca nut
(AN) contains areca alkaloids, polyphenols and tannins.
Considerable evidence suggests that areca alkaloids are
the major factors for AN toxicity. AN is reported to
contain more than 4 alkaloids, including arecoline, are-
caidine, guvacoline and guvacine.34 Oral keratinocytes
and fibroblasts appear to be the major target cells
attacked by BQ ingredients. BQ ingredients have been
shown to induce cytotoxicity, DNA strand breakage,
and DNA-protein cross-linkage of oral keratinocytes
and fibroblasts.34–36 Repeated and continuous expo-
sure of oral mucosal cells to BQ ingredients will lead
to impairment of cellular defense systems such as
antioxidants, glutathione peroxidase, and superoxide
dismutase. The induction of DNA damage and the
inhibition of DNA repair will promote the fixation 
of mutated nucleotides, leading to the formation of 
initiated cells.37,38 BQ ingredients increase mtDNA
mutation in human oral tissues, and that accumula-
tion of mtDNA deletions and subsequent cytoplasmic
segregation of these mutations during cell division
could be an important contributor to the early phase
of oral carcinogenesis.39 Also, BQ induces the chromo-
somal imbalances that occur in oral carcinoma and is
associated with their clinical implications. The prelim-
inary findings of a lower incidence of loss of 4q and
gain of 8q in BQ-associated tumors compared to non-
BQ-associated tumors might provide insight into the
carcinogenic effect of BQ.40 Many studies have been
designed to directly analyze the carcinogenicity of BQ
ingredients in experimental animals. Repeat brushing
of the hamster cheek pouch with a dimethyl-sulfoxide
(DMSO) extract of AN 3 times/week for 21 weeks led
to the development of tumors in 38% of test animals,
and leukoplakia in 90% of test animals. Direct painting
of DMSO extract of AN also induced early malignant
changes in the hamster cheek pouch.41–43
New Markers and Tools for Oral Cancer
Detection and Treatment
The last 10 years has seen a shift in diagnostic methods
from the histopathologic to the molecular level.44–49
With advances in modern molecular biology tech-
niques, many new markers for oral cancer have been
found and studied. Significant momentum has been
seen in the exploration of P53, P16, telomerase, and
so on in many cancer research groups. For example,
using in situ hybridization (ISH) and telomeric repeat
amplification (TRAP) assay, a gradual increase in telom-
erase activity was observed in the malignant transfor-
mation process of oral cancer.39 Loss of retinoic acid
receptor (RAR)-β expression in the malignant trans-
formation of oral cancer has been reported by analyz-
ing the expression of RAR-β using ISH of RAR-β
antisense riboprobe in oral cancer and adjacent non-
cancerous matched tissues to correlate with their 
clinicopathologic features.47–49 With the great advance-
ment in disclosing pieces of the puzzle of cancer
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development, the next generation of cancer screening
methods will favor a more efficient and reliable tool
based on previous contribution of scientists. The newly
developed microarray/gene chip technology with more
reliable/predictable tumor markers will encourage us
to seek a new approach to cancer screening.50 Current
formal diagnosis of oral cancer is still based on the
pathology report from biopsy. Beyond just being used
for staging, we expect microscopic observations to
provide more information about potential early nodal
metastasis, tumor behavior, and clues to fine-tune
treatment modality or even to predict prognosis.
By revealing the story of oral carcinogenesis, the
normal oral epithelial cells should go through the steps
from abnormal cells to precancer or cancer cells in situ,
stroma invasion, vascular permeation and metastasis.
What we see as a huge tumor in the oral cavity can be
further microscopically dissected based on many
molecular events equivalent to various pathological
covariates.51,52 These pathological covariates might
potentially provide some clues for treatment planning.
The following are some interesting findings proposed
by our research team. RAR-β is an important differ-
entiation marker of oral epithelium. We used ISH to
discover that the loss of expression in buccal squa-
mous cell carcinoma could relate to a more advanced
histopathologic grade of tumor.49 We investigated the
significance of histopathologic factors on clinical out-
come in squamous cell carcinoma of buccal mucosa
and found that perineural invasion and lymphovascular
permeation significantly affects local recurrence. Tumor
thickness significantly relates to staging of tumors and
the survival of cases. We further investigated the patho-
logic risk factors affecting nodal metastasis in tongue
cancer. We found that differentiation, invasion depth,
perineural invasion, and lymphovascular permeation
significantly affect nodal metastasis in tongue cancer.
Therefore, patients in early stages I or II with such
pathologic covariates may need more appropriate early
neck treatment.53
We also found differential expression of adhesion
molecules E-cadherin in metastatic lesions compared
to primary OSCC. This implies that disintegration of
cellular junctions of cancer should correlate significantly
to the degree of malignancy and its ability to enter into
blood and lymphatic vessels.54 Not only the cancer cells
themselves but also the stroma tissue was thought to
be important in oral carcinogenesis. The functional
single nucleotide polymorphism (SNP) in the MMP-3
gene is associated with oral submucosal fibrosis sus-
ceptibility. The MDM2 SNP and p53 codon 72 SNP
are independent and useful prognostic factors in
OSCC patients receiving postoperative radiotherapy.
The genotype of these cases may have higher resistance
to radiotherapy. The functional SNP of the MMP-9
gene is associated with risk of OSCC in younger male
AN users. Young AN chewers with this genotype may
have a higher oral cancer risk. Correlation between
functional genotype in the MMP-1 promoter was
found to be associated with the risk of OSCC.23,55–57
Due to the lack of unique molecular markers in
oral cancer, a diversified phenotype/genotype of OSCC
cases needs more powerful tools to demonstrate its
gene expression profiles linking to their clinical behav-
iors.7,58,59 Conventional TNM staging obviously does
not provide all the needed information.53 If we could
further analyze the gene expression profiles underlying
the pathologic covariates of what we see under the
microscope, it would aid greatly in directing more
appropriate treatment modalities such as the need for
neck dissection, postoperative radiation chemotherapy
or even target therapy.
Future Work
OSCC is the fourth leading malignancy in men in
Taiwan due to the popularity of BQ chewing. There
are more than 2.5 million BQ chewers in our country
who are at high risk for OSCC. Despite advances in
cancer treatment and diagnosis in the past decades,
the prognosis for OSCC remains dismal. Most OSCC
patients die of recurrence or metastasis. Therefore,
much remains to be done to elucidate the pathogene-
sis associated with BQ chewing and to improving the
therapies for OSCC. Among multiple AN ingredients,
AN extract (ANE) was classified as a group I carcinogen
by the International Agency for Research on Cancer.
Our previous studies have shown that ANE modulated
signaling activation, leading to karyotypic alterations
and increase in the aggressiveness of oral cancer cells.
The gene expression signatures associated with metas-
tasis of BQ-associated OSCC have been established in
our previous research.24,29,31,34,36,41 We also adopted
brushing samples to identify copy number amplifica-
tion of oncogenes in the oral epithelial cells from BQ
chewers.18 On the basis of previous achievements, the
ongoing pathogenetic projects are the following: (1)
to characterize the oncogenic potential of several
ANE-modulated genes, and to specify their roles in
OSCC recurrence and metastasis; (2) to investigate
the impact of ANE on the microenvironment for the
genesis and progression of OSCC; and (3) to develop
molecular analysis for oral brushing and serum sam-
ples from high-risk BQ chewers or OSCC patients in
identifying markers for early diagnosis and prognostic
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prediction. We believe that by the devotion of clini-
cians and scientists, a new approach to oral cancer will
no longer be a dream.
The program of cancer detection and screening is
like a war, and should be backed by full government
support, cooperation of school education, news media,
medical services, and general awareness from the whole
population. Care should especially be taken in policy
and strategic planning and in performing the cancer
detection/screening examinations. As health care work-
ers, we need to know the important role of our pro-
fession in the screening and detection of oral cancer.
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